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CHAPTER I 
 
INTRODUCTION 
 
The epidermal growth factor (EGF) receptor, also known as ErbB-1, is a 
transmembrane tyrosine kinase that belongs to the eukaryotic protein kinase 
superfamily.  The EGF receptor was first isolated in 1979 and cloned and 
sequenced in 1984 as the target of epidermal growth factor, which was isolated 
in 1960 by Stanley Cohen (Cohen 1960; Carpenter 1979; Ullrich, Coussens et al. 
1984).  Early studies showed EGF-dependent phenotypes in cell culture and in 
the mouse, which suggested an important role for the EGF receptor in 
development (Levi-Montalcini and Cohen 1956; Cohen 1962).   
The EGF receptor has important functions not only in development, but 
also in pathologies such as cancer. Members of the ErbB family include ErbB-2, 
ErbB-3, and ErbB-4(Linggi and Carpenter 2006). Although highly homologous, 
the ErbBs do exhibit major differences in function.  ErbB-2 is sometimes referred 
to as the ‘orphan’ receptor because it binds no known ligand and is the preferred 
dimerization partner for ErbB heterodimers (Klapper, Glathe et al. 1999).  ErbB-3 
contains an inactive kinase which is proposed to result from several 
nonconservative residue changes compared to ErbB-1(Guy, Platko et al. 1994).   
ErbB-4 undergoes sequential cleavage to produce a functional soluble kinase-
active intracellular domain fragment (Ni, Murphy et al. 2001; Sardi, Murtie et al. 
2006).     Deletion of any of the ErbB receptor genes in murine transgenic models 
results in lethality at various developmental stages, and thus underscores the 
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requirement of these proteins in normal development.  The EGF receptor is 
expressed in nearly all non-hematopoietic tissues and its activation results in a 
wide variety of cellular responses based on expression pattern and ligand 
availability (Riese and Stern 1998; Linggi and Carpenter 2006)   Specifically, 
EGF receptor-deficient mice exhibit phenotypic defects in lung, gastrointestinal, 
skin, and eyelid development (Miettinen, Berger et al. 1995; Sibilia and Wagner 
1995; Threadgill, Dlugosz et al. 1995).  Sequence homology identified between 
the EGF receptor and its viral counterpart v-erbB in 1984, implicating the 
receptor in oncogenesis (Downward, Yarden et al. 1984).  The role of mutant or 
aberrant EGF receptor expression in cancer has since been verified (Holbro, 
Civenni et al. 2003). 
In this chapter I will review the current knowledge of EGF receptor 
structure and function.  
 
EGF Receptor Structure 
The epidermal growth factor receptor is the archetype for the structurally 
and functionally related ErbB family of receptor tyrosine kinases.   The EGF 
receptor, also referred to as ErbB-1, is a Type I single-pass transmembrane 
glycoprotein and shares an architecture similar to ErbB-2, -3, and -4.  The EGF 
receptor is initially synthesized as a transmembrane precursor polypeptide from 
which the 24 residue N-terminal signal sequence is cleaved (Ullrich, Coussens et 
al. 1984).  Maturation of the receptor involves N-linked glycosylation of ten 
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consensus ectodomain asparagine residues within the endoplasmic reticulum.  
The mature 170kDa EGF receptor consists of a large ectodomain (70 kDa 
polypeptide, plus an additional ~35kDa in N-linked carbohydrate moieties) , 
composed of subdomains designated I-IV, a short 23 residue alpha-helical 
transmembrane domain (TM), and a 60kDa intracellular domain (ICD), which 
contains a cytosolic juxtamembrane (JM) region, tyrosine kinase domain (TKD), 
and a carboxyterminal region (CT)(Figure I).   
The influence of each of these subdomains and regions on receptor dimerization 
and activation is reviewed in this chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
          
Figure 1.  EGF Receptor Schematic.  TM, transmembrane domain; JM 
juxtamembrane region; TKD, tyrosine kinase domain; CT, carboxyterminus. 
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Ectodomain 
The ectodomain of ErbB-1 is composed of four subdomains and functions 
in dimerization of the receptor, a critical step required for tyrosine kinase 
activation.  The mechanism for dimerization is mediated by ligand-binding to 
subdomains I and III of the ectodomain.  Subdomains I and III are required for 
ligand binding, as evidenced by both cross-linking and chimeric chicken-human 
protein studies (Lax, Bellot et al. 1989; Woltjer, Lukas et al. 1992; Summerfield, 
Hudnall et al. 1996).  These biochemical results have been confirmed by 
crystallographic data illustrating ligand-bound ErbB ectodomains (Garrett, 
McKern et al. 2002; Ogiso, Ishitani et al. 2002; Ferguson, Berger et al. 2003).  
Ligand-binding results in a conformational change in the ectodomain such that 
the 10 residue dimerization arm of subdomain II, a necessary component of 
receptor dimerization, is exposed to mediate contacts between ectodomain 
monomers.  The dimerization arm is necessary, but not sufficient to drive 
receptor dimerization, as ligand is still required to induce dimer formation of 
extracellular domains (Elleman, Domagala et al. 2001; Garrett, McKern et al. 
2002).  However, mutational disruption of the dimerization arm results in 
increased dissociation of ligand as well as a decreased signaling capacity, 
implicating a role for the dimerization arm in the stabilization of the ligand-bound 
receptor (Mattoon, Klein et al. 2004). 
In addition to the role of ligands in dimerization of the receptor, the 
glycosylation state of specific asparagine residues in the ectodomain regulates 
‘tethering’ of subdomains in the ‘closed’ conformation.  The ‘tethered’, or closed 
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ectodomain conformation, is consistent with an unliganded inactive receptor 
state.  The untethered, or extended ectodomain conformation, is brought about 
by ligand binding between subdomains I and III, resulting in a 130º movement of 
subdomain I as it ‘swings’ from the tethered to extended conformation and 
exposure of the dimerization arm (Figure 2). 
The cysteine-rich subdomains II and IV have been traditionally thought to 
serve as intramolecular scaffolds (Abe, Odaka et al. 1998).  Although subdomain 
II contains eight disulfide bonds, it not only contributes to the structural 
maintenance of the ectodomain, but also contains the aforementioned 
dimerization arm that is necessary for ligand-induced dimerization.  Like 
subdomain II, subdomain IV also contributes to the organization of the 
ectodomain structure with seven disulfide bonds, but its deletion results in 
increased ligand affinity, suggesting a role in modulation of ligand-binding 
(Elleman, Domagala et al. 2001).  Indeed, both crystallographic and biochemical 
studies have confirmed that this modulation is mediated by interdomain ‘tethers’ 
between subdomains II and IV (Cho and Leahy 2002; Ferguson, Berger et al. 
2003).   
Transmembrane Domain 
The transmembrane domain is a 23 residue alpha helix.  This domain is 
thought to play a regulatory role in the spatial orientation and association of ErbB 
receptors (Sharpe, Barber et al. 2002).  This short sequence contains two 
GXXXG motifs originally described in the TM domain of glycoporin A (Figure 3).   
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Burgess et al.  Mol Cell 12:  541-552  (2003) 
Figure 2 .  Schematic of EGF receptor Ectodomain Rearrangement 
upon Ligand-binding.  Inactive ectodomain monomers are ‘tethered’ by 
glycosylation and intramolecular interactions.  Upon ligand binding (blue 
oval) to  subdomains I and III, conformational rearrangement of the 
ectodomain exposes the dimerization arm of subdomain II which then makes 
contacts with another ectodomain monomer in the extended conformation.                                                                                                                                               
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Two GXXXG motifs exist in the TM domains of all ErbBs, with the 
exception of ErbB-3.    Mutational analysis demonstrates that these GXXXG 
motifs are required for interactions between TM domains of ErbB receptor 
monomers and are thought to facilitate dimerization (Mendrola, Berger et al. 
2002).  Mendrola et al. were able to discern a rank order for homodimerization of 
ErbB TM domains by employing a ToxR-chloramphenicol acetyltransferase 
(TOXCAT) assay.  This assay employs the use of chimeras composed of the 
ErbB TM sequences and the transactivating sequences of the cholera ToxR 
protein which is only functional as a dimer.  The TM domain of ErbB-4 was found 
to homodimerize most efficiently, while ErbB-1 and -2 were found to be 
equivalent in homodimerization capacity, and finally, the ErbB-3 TM domain 
homodimerized the least efficiently.  This system was not used to assess the 
roles of the TM domains of ErbB family members in heterodimerization. 
The mutation of Val664 to Glu in ErbB-2 from rat glioblastoma was 
reported to result in constitutive dimerization and activation of the receptor 
(Bargmann, Hung et al. 1986; Bargmann and Weinberg 1988).  The equivalent 
‘Neu’ mutation in human ErbB-2  (V659E) recapitulates the constitutive activation 
of ErbB-2 observed in rat glioblastoma (Segatto, King et al. 1988).   Surprisingly, 
the ‘Neu’ mutation in human ErbB-2 results in a significant decrease in 
homodimerization as assessed by the TOXCAT assay, suggesting that the 
mutation drives activation not by enhancing dimer stability, but rather by altering 
the conformation of the receptor (Mendrola, Berger et al. 2002). 
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Tyrosine Kinase Domain 
The tyrosine kinase domains of ErbB receptors are bi-lobal structures that 
contain elements conserved across the protein kinase superfamily.  The major 
elements  consist of a nucleotide-binding pocket, an activation loop, and an αC-
helix (Hanks and Hunter 1995).  The TKD is responsible for catalyzing hydrolysis 
of γ-phosphates of ATP for subsequent trans-phosphorylation of tyrosyl-
containing substrates, including tyrosine residues located within the receptor 
carboxy terminus (Buhrow, Cohen et al. 1982; Cohen, Ushiro et al. 1982; 
Buhrow, Cohen et al. 1983; Downward, Waterfield et al. 1985; Honegger, Kris et 
al. 1989; Honegger, Schmidt et al. 1990).  A functional tyrosine kinase is required 
to elicit EGF-dependent responses (Chen, Lazar et al. 1987).   
Functional perturbation of catalysis, most commonly by mutation, can lead 
to kinase-dead or constitutively active phenotypes.  Mutation of Lys721, yields a 
kinase negative receptor by preventing ATP binding within the nucleotide binding 
pocket of the receptor (Russo, Lukas et al. 1985).  Mutation of Thr766 (Thr790 
with signal sequence), commonly referred to as the ‘gatekeeper’ residue, to Met 
results in constitutive activation of the tyrosine kinase by increasing the affinity of 
the receptor for ATP (Kobayashi, Boggon et al. 2005; Yun, Boggon et al. 2007).   
Structurally, the TKD is divided into a beta sheet-rich N-lobe and an alpha-
helical-rich C-lobe.  Until recently, the TKD was thought to dimerize in the same 
fashion as the ectodomain, as a symmetric dimer.  However, research by the 
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Figure 3.  ErbB TM Domain Alignment.  ErbB TM domain 
sequences are aligned with glycoporin A for comparison.  GXXXG 
motifs are shaded gray and glycines at which substitutions result 
in significant reduction in dimerization are shaded black. 
 
Mendrola et al.  JBC 277:4704-4712 (2002) 
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Kuriyan group in 2006, described an allosteric mode of activation in which TKDs 
form asymmetric dimers (Zhang, Gureasko et al. 2006).  The precedent for 
asymmetric dimerization is supplied by the cyclin-Cylcin dependent kinase 
systems, in which a contact interface between opposing lobes of cyclin and cyclin 
dependent kinase monomers results in activation of the cyclins.  For the EGF 
receptor, both crystallographic and biochemical data show that the C-lobe of a 
donor monomer contacts the N-lobe of an acceptor monomer to result in tyrosine 
kinase activation of the acceptor.  Experimental mutations within the asymmetric 
TKD dimer interface of the intact EGF receptor demonstrate that this allosteric 
mechanism applies to the capacity of the full-length receptor to respond to EGF.  
This may explain how mutations in the ErbB-3 TKD activation interface 
contributes to an inactive ErbB3 kinase, but allows for activation of ErbB family 
members, namely ErbB2, by the ErbB3 kinase.  In this case, ErbB-3 monomers 
may serve as “donor” monomers to activate ErbB-2 “acceptor” monomers.  
 Data suggests that the TKD-proximal juxtamembrane region and carboxy 
terminus serve regulatory roles in the allosteric mode of EGF receptor tyrosine 
kinase activation.  Thiel and Carpenter (2007) demonstrate that the JM is 
required for kinase activation by showing loss of tyrosine phosphorylation of the 
EGF receptor upon deletion of the JM.  The contribution of individual residues of 
the JM region to tyrosine kinase activation was not assessed in the study by 
Thiel and Carpenter (2007) and is the focus of research presented in Chapter III.  
Early studies from Welsh et al. (1991) demonstrated an increase in tyrosine 
kinase activity upon deletion of the carboxy terminus, indicating the presence of 
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an autoinhibitory domain.  Jura et al. (2009) have identified residues of the EGF 
receptor carboxy terminus involved in mediating intramolecular autoinhibitory 
contacts.  The role of receptor autophosphorylation in loss of autoinhibition has 
not been examined. 
 
Carboxyterminus 
The carboxyterminus (CT) of the EGF receptor, spanning residues 996-
1186, contains multiple sites of autophosphorylation as well as ubiquitination.  
Both of these post-translational modifications mediate effects on receptor 
signaling, as described below (Ligand-Dependent EGF receptor Kinase 
Activation and Signaling).    
Besides the involvement of post-translational modifications in receptor 
behavior, truncation analysis showed that the CT mediates negative regulation of 
EGF receptor kinase activity (Walton, Chen et al. 1990).  The structural basis for 
this CT-dependent negative regulation is now apparent.  Jura et al. describe an 
autoinhibitory role for CT residues by illustrating intramolecular contacts of CT 
residues with C-lobe residues of the TKD via an inactive symmetric EGF receptor 
crystal structure (Jura, Endres et al. 2009).  This inactive symmetric dimer is 
proposed to shift to the active asymmetric dimer state by increased local receptor 
concentration brought about by ligand-induced receptor oligomerization.  The 
mechanism involves displacement of the intramolecular autoinhibitory CT 
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residues by the activating intermolecular juxtamembrane residues of a proximal 
kinase monomer (Figure 4).   
 
Juxtamembrane Region 
The 38 residue juxtamembrane (JM) region of the EGF receptor contains 
a variety of signaling and sorting motifs.  A more extensive discussion of the 
juxtamembrane region, especially its role in EGF receptor activation, will be 
presented in Chapter 3 of this dissertation. 
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adapted from Jura et al.  Cell  (2009)  
Figure 4.  Role of Carboxy Terminal Residues in Autoinhibition of EGF Receptor 
Activation.  The inactive symmetric dimer is maintained by intramolecular contacts of c-
termial residues (red) with the N lobes of receptor monomers.  Addition of EGF shifts the 
dimer equilibrium to the active asymmetric dimer, in which activating residues in the 
juxtamembrane region (green) occupy the same positions as the autoinhibitory c-terminal 
residues in the inactive state. JM-A (pink lines) denotes residues 645-663, also described as 
the exon-17 encoded portion of the JM, that immediately preceeds the Juxtamembrane 
Activation Domain (JMAD).  The JM-A segments of the JM region are proposed to form 
antiparallel alpha helices in the active asymmetric dimer (pink cylinders, right panel). 
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EGF Receptor Function 
Ligand-Dependent EGF Receptor Kinase Activation and Signaling 
One of the most basic functions of transmembrane proteins is to mediate 
cellular responses to extracellular stimuli.   Ligand-binding initiates EGF receptor 
responses.  The seven known EGF receptor ligands are EGF, epigen, epiregulin, 
betacellulin, heparin-binding EGF, amphiregulin, and transforming growth factor 
α. Generation of mature diffusible ligands occurs by proteolysis of the 
transmembrane pro-forms at the cell surface (Schneider and Wolf 2009).  
Ligand-binding to EGF receptor results in the conformational rearrangement of 
the ectodomain of the receptor from a tethered to an untethered form, ultimately 
leading to its activation (Figure 2).  
The receptor possesses tyrosine kinase activity whereby ATP-binding in 
the nucleotide-binding pocket of the intracellular tyrosine kinase domain is 
followed by hydrolysis of the terminal γ-phosphate of ATP and 
autophosphorylation of c-terminal tyrosine residues in trans or phosphorylation of 
exogenous substrate proteins, such as phospholipase-C γ1.  The receptor 
contains seven known sites of tyrosine autophosphorylation that are contained in 
the carboxyterminus, as well as one Src phosphorylation site (Tyr845) located on 
the activation loop (Figure 4)(Biscardi, Maa et al. 1999).  Tyrosine kinase activity 
of the receptor is separable from receptor autophosphorylation. In cells the CT- 
truncated receptor maintains its capacity to phosphorylate substrates.  In in vitro 
kinase assays employing the purified TKD, exogenous substrates are efficiently 
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phosphorylated (Walton, Chen et al. 1990; Zhang, Gureasko et al. 2006).    The 
function of tyrosine phosphorylation of the receptor is activation of downstream 
signaling pathways by recruitment of proteins containing either Src homology-2 
(SH2) domains or phosphotyrosine binding (PTB) domains (Figure 5).  For 
example, PLCγ-1 is recruited to the receptor by its SH2 domain, which associates 
with pTyr992.  PLCγ-1 is then tyrosine phosphorylated and activated by the 
receptor kinase, resulting in hydrolysis of phosphatidyl inositol-4,5-
bisphosphosphate to form the second messengers inositol 1,4,5-trisphosphate 
and diacylglycerol.  Another example is the recruitment of the adaptor protein 
Grb2 to pTyr1068.  Grb2 then acts as an intermediary in the activation of the 
Ras/MAPK pathway.  The PTB- and SH2-containing adaptor protein Shc can be 
recruited to EGF receptor phosphorylated at either Tyr1148 or Tyr1173.  This 
propagation of signaling leads to cellular responses, such as proliferation and 
survival(Yarden and Sliwkowski 2001).   
EGF receptor-propagated signaling pathways include the mitogen-
activated protein kinase (MAPK) pathway, phosphoinositide 3-kinase (PI3K) 
pathway, and signal transducer and activator of transcription (STAT) pathway.  
Aberrant upregulation of MAPK, PI3K/Akt, and STAT signaling pathways is a 
common feature of EGF receptor-dependent cancers. 
The general mechanism of MAPK activation is described above, where 
recruitment of the constitutively associated Grb2-Sos complex to sites of tyrosine 
phosphorylation of the receptor initiates the MAPK signaling cascade.   
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The phosphoinositide 3-kinase pathway, sometimes referred to as the 
PI3K/Akt pathway, is initiated downstream of activated EGF receptor by the PLC-
γ catalyzed generation of the second messengers phosphatidylinositol 4,5-
bisphosphate (PIP2) and diacylglycerol (DAG).  DAG then activates PI3K, which 
then directly activates Akt.  Akt is known to have a variety of substrates which, 
when phosphorylated, result in cellular survival.  Such Akt substrate proteins 
include mTOR and XIAP, which are known to be involved in protein synthesis 
and inhibition of apoptosis, respectively.   
The signal transducer and activator of transcription (STAT) proteins are 
nucleo-cytoplasmic proteins that can be phosphorylated directly by the EGF 
receptor.  Phosphorylated Stat proteins are dimeric and localized to the nuclear 
compartment where they mediate cellular survival and proliferation via 
transcriptional activation on gamma activated sites.   
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Figure 4.  EGF Receptor Intracellular Domain.  Autophosphorylation 
sites are indicated.  The Src phosphorylation site Tyr 845 is also 
indicated.  Examples of known SH2-containing proteins, PLCγ-1 and 
Grb2, and their docking sites are shown, as well as the PTB- and SH2-
containing protein Shc.  
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Receptor Trafficking 
Activated ErbB receptor dimers cluster into clathrin-coated pits, which 
leads to receptor internalization (Vieira, Lamaze et al. 1996).  Receptor 
internalization has been shown to require the endocytic epsin proteins and the 
cargo recognition protein AP-2(Rappoport and Simon 2009).  The AP-2 protein 
associates directly with the EGF receptor and data from Jura et al. (2009) 
suggest that specific carboxy terminal residues are responsible for this 
interaction.  Association of activated receptor with epsin or epsin-15 via AP-2 
results in localization within early endocytic vesicles.  Ubiquitin moieties present 
on the EGF receptor after activation have also been demonstrated to mediate 
interaction with epsin proteins (Stang, Blystad et al. 2004; Kazazic, Bertelsen et 
al. 2009).  Thus, data demonstrates a role for ubiquitin in the internalization of 
activated receptor populations.   
Internalized receptors have different fates, which are dependent on cell 
type, receptor concentration, cytosolic factors, and post-translational 
modifications (Sorkin and Goh 2009).  As depicted in Figure 5, the majority of 
internalized EGF receptor is subject to lysosomal degradation (Sorkin and Von 
Zastrow 2002).    Receptor recycling is also observed, as internalized receptor is 
sorted back to the plasma membrane (Sorkin and Von Zastrow 2002).  
Finally, and of particular importance in Chapter 4, activated, mature EGFR 
is trafficked to the mitochondria or  nucleus (Lin, Makino et al. 2001; Boerner, 
Demory et al. 2004; Lo, Hsu et al. 2005).  The mechanism by which mature intact 
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EGF receptor is trafficked to the nucleus is unknown.  A more extensive 
discussion of nuclear trafficking of the EGF receptor will be presented in Chapter 
4 of this dissertation. 
 
EGF Receptor in Cancer 
The EGF receptor has described roles in various cancers, such as head 
and neck, breast, brain, gastrointestinal, and lung cancers (Yarden and 
Sliwkowski 2001).  The receptor mediates tumorigenesis by amplification and/or 
mutation.  The tumorigenesis resulting from amplified receptor is due to the 
increased activation and proliferative signaling brought about by elevated 
receptor concentrations, as seen in glioblastoma (Yamazaki, Fukui et al. 1988; 
Zawrocki and Biernat 2005).  
In addition to amplification, mutation of the receptor results in 
tumorigenesis.  The most common deletion mutation (first identified in 
glioblastoma) is known as ErbB-1-VIII, in which exons 2-7 (that encodes a large 
portion of the ectodomain) are missing.  This results in a constitutively active 
receptor (Wong, Ruppert et al. 1992; Frederick, Wang et al. 2000).  In lung 
cancer, small deletions and point mutations were found in the tyrosine kinase 
domain of the EGF receptor that renders the receptor constitutively active 
(Sharma, Bell et al. 2007).   
Both amplified wild-type receptors and mutant receptors are the focus of a 
variety of therapeutics.  Two categories of therapeutics targeted towards ErbB-1 
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LIGAND-DEPENDENT EGFR TRAFFICKING 
Figure 5.  Ligand-dependent EGFR Trafficking Schematic. Major trafficking 
pathways of activated cell-surface EGFR are indicated and include recycling, 
degradation, and the novel ER-localization and Sec61-dependent nuclear 
localization. 
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are currently approved for clinical use and/or are in clinical trials.  The first 
category of ErbB-1-directed therapeutics is humanized monoclonal antibodies 
directed to the ectodomain of the receptor, such as Erbitux (cetuximab/C-225, 
Bristol-Myers Squibb).  This antibody is currently FDA approved for the treatment 
of both colorectal and head and neck cancers.  Antibodies directed towards the 
ErbB-1 ectodomain function by preventing ligand-binding and dimerization of the 
receptor.   
Small molecule inhibitors represent a second avenue of receptor 
inhibition.  All currently available EGF receptor tyrosine kinase inhibitors (TKIs) 
are ATP-mimetics that compete with ATP for binding to the nucleotide-binding 
pocket.  Two basic classes of TKIs are reversible and irreversible small 
molecules.   Examples of the reversible TKIs include gefitinib (Iressa, Astra 
Zeneca) and erlotinib (Tarceva, Genentech).  The irreversible inhibitors, such as 
HKI-272, form a covalent linkage with Cys727 in the ATP-binding pocket, thus 
preventing ATP-mediated autophosphorylation.     Unfortunately, examination of 
patients indicates that while TKIs may be preliminarily efficacious, resulting in a 
temporary reduction of in the number and size of tumors, mutations frequently 
arise within the EGF receptor TKD that allow activation in the presence of small 
molecule inhibitors - a phenomenon known as acquired resistance.  For this 
population of patients, progression of disease is observed.  The most frequently 
occurring acquired resistance mutation in patients treated with EGF receptor-
directed TKIs is T766M (Balak, Gong et al. 2006; Kosaka, Yatabe et al. 2006).  
Interestingly, the structurally equivalent residue in the Bcr-Abl protein, Thr 315 is 
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also frequently mutated upon treatment of chronic myelogenous leukemia with 
Bcr-Abl ATP-mimetics such as imatinib (Gleevec) (Shah, Nicoll et al. 2002).   
EGF receptor nomenclature used in this dissertation will refer to the 
mature receptor sequence, that is, receptor from which the signal peptide has 
been cleaved, resulting in a minus 24 amino acid difference from the cDNA-
derived sequence.  For example, the gatekeeper mutation is referred to as either 
T766M (mature) or T790M (cDNA) in the literature.   
Data presented in this dissertation is directed toward elucidating both the 
role of the juxtamembrane region in the allosteric activation of the EGF receptor 
and the role of the p97 AAA-ATPase in mediating ligand-dependent nuclear 
trafficking of the intact receptor.  Chapter III is dedicated to the identification of 
juxtamembrane residues required for tyrosine kinase activation.  Biochemical and 
biological experiments are presented that demonstrate the existence of a 
juxtamembrane activation domain that is required for receptor activation as well 
as novel patient mutations within this new domain that result in constitutive 
tyrosine kinase activation and tumorigenesis in a xenograft model.  The focus of 
Chapter IV is the elucidation of the requirement of the AAA-ATPase p97 for 
ligand-dependent nuclear localization of intact receptor.  Biochemical data is 
supplied to support this finding. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell Culture and Transfections 
 
Transient transfection for expression in mammalian cells was carried out 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions.  Two µg of expression plasmid was used per 60mm dish.  Transient 
expression of full-length EGF receptor in NIH3T3 cells was carried out using a 
DNA: Fugene6 (Roche) ratio of 1.5µg:4.5µl, according to the manufacturer’s 
instructions.  To assess ligand-dependent EGFR activation, transfected cells 
were serum starved overnight and treated with 50ng/ml EGF.  
 
Reagents, Antibodies, Cell lines, and Plasmids 
 
NIH3T3, Cos-7, and 293 cells were obtained from the American Type 
Culture Collection and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco) supplemented with 10% fetal bovine serum (Atlanta Biologicals) 
at 37°C at 5% CO2.  EGF was purchased from R&D Systems. 
 Monoclonal anti-Flag was purchased from Sigma.  Polyclonal anti-EGFR 
pY1173 was purchased from Santa Cruz Biotechnologies.  Polyclonal anti-EGFR 
was purchased from Millipore.  Anti-EGFR Ab-3 was purchased from LabVision. 
Monoclonal anti-p97 was purchased from Fitzgerald Industries.  The respective 
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HRP-conjugated secondary antibodies were purchased from Zymed.  Alexa-488 
goat-anti mouse was purchased from Molecular Probes.  For immunoblot 
detection, enhanced chemiluminescence reagent from Perkin Elmer Life 
Sciences was used.  Stripping and reprobing of blots was performed according to 
the manufacturer’s recommendations. 
 The plasmid encoding EGFR-ICD-flag was cloned as previously described 
(Thiel and Carpenter 2007) and its sequence verified.  Site-directed mutagenesis 
was employed to make all mutants with the use of PfuUltra polymerase 
(Stratagene).  Flag-EGFR plasmid was a gift from Tony Burgess (Ludwig Institute 
for Cancer Research) and was fully sequenced.  The pBABE retroviral vectors 
used in EGF receptor expression for soft agar and xenograft assays were 
purchased from Addgene.  Site-directed mutagenesis of pBABE-EGFR was 
employed to make pBABE-EGFR-V665M.  All shRNA constructs were purchased 
from Open Biosystems.  All mutations were confirmed by fully sequencing each 
construct.   
 
Cell Lysis and Immunoblotting 
Cells at 80-90% confluence were serum-starved and either untreated or 
treated with EGF as indicated, and then washed with phosphate-buffered saline 
(PBS).  Cells were scraped and lysed in ice-cold lysis buffer containing 1% 
Triton, 10% glycerol, 50mM Hepes, pH 7.2, and 100mM NaCl, 1mM EDTA, 1mM 
sodium orthovanadate, 1mM phenylmethylsulfonylfluoride, 10ug/mL aprotinin, 
and 25ug/mL leupeptin.  Lysates were cleared by centrifugation at 13,000 x g for 
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10 minutes at 4°C.  SDS sample buffer was added to lysates and samples were 
boiled for 5 minutes.  Samples were then subjected to SDS-PAGE on 8% 
polyacrylamide gels, transferred to polyvinylidene fluoride membranes and 
immunoblotted. 
Nuclear and non-nuclear fractions were prepared from 293 cells.  Cells 
were washed with phosphate buffered saline.   One mL of Buffer B (Buffer A 
(10mM Hepes, pH 7.9, 1.5mM MgCl2, 10mMKCl, 1mM EDTA, 1mM sodium 
orthovanadate, 1mM phenylmethylsulfonylfluoride, 10ug/mL aprotinin, and 
25ug/mL leupeptin) plus 1% NP-40) was added per 10cm dish and cells were 
scraped into microfuge tubes.  Tubes were incubated on ice and vortexed at 
~50% speed 3 times for a duration of 5 seconds per vortex within a 10 minute 
period.  Cells were subjected to centrifugation at 400 x g for 4 minutes at 4ºC.  
800 µL of supernatant was transferred to a fresh microfuge tube and rocked for 
30 minutes 4ºC.  The non-nuclear fraction was collected after centrifugation for 
10 minutes at 13,000 x g.  The pellet resulting from the initial centrifugation step 
was washed with Buffer B twice, then pellets were incubated 30 minutes on ice in 
of 50uL Buffer C (65% Buffer A, 25% glycerol, 10% 5M NaCl).  The soluble 
nuclear fraction was collected from the resulting supernatant after centrifugation 
for 5 minutes at 13,000 x g. 
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Retrovirus-Mediated Gene Transduction and Colony Formation Assay 
The pBABE-puro retroviral vector containing the coding sequences for 
wild-type EGFR, or receptor mutants V665M, L834R, or D813A were used to 
produce virus-containing supernatants from transfected Phoenix cells.  Viral 
supernatant was used to transduce NIH3T3 cells in the presence of 5µg/ml 
polybrene.  Equal amounts of retrovirus containing wild-type EGFR, or receptor 
mutants V665M, L834R, D813A, or vector alone were used for infection.  NIH 
3T3 cells stably expressing wild-type EGFR or receptor mutants were selected 
using 2ug/mL puromycin for 7 days.  Cells expressing equal concentrations of 
receptor were sorted via FACS by staining with a non-ligand interfering 
ectodomain antibody (anti-EGFR Ab-3, LabVision) and then seeded at 8 x 103 
cells per well in the 0.4% top layer of a 12-well plate.  Cells were cultured in 10% 
FBS with or without 50ng/ml EGF.  Medium was changed every two days and 
colonies were counted at 3 weeks using an Oxford Optronix Gelcount. 
 
In Vivo Tumorigenicity 
To determine the capacity of NIH3T3 cells to form tumors in vivo when 
stably expressing pBabe-puro vector, wild-type, or V665M EGFR, nude mice (4 
mice per cell type) received four dorsal subcutaneous injections, one in each 
quadrant, with either 1.25 x 105, 2.5 x 105, 5 x 105, or 1 x 106 tumor cells in 200 µl 
PBS.  Tumor growth was then analyzed over time, as plotted in Figure 5.  Three 
months post tumor cell injection, the mice were sacrificed and the number and 
27 
 
size of tumors were evaluated.  Tumor volumes were calculated using the 
following formula: tumor volume (mm3) = (length x width2)/2 (Chen, Su et al. 
2005).  All animal protocols were approved by Vanderbilt University Medical 
Center Institutional Animal Care and Use Committee. 
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CHAPTER III 
 
THE JUXTAMEMBRANE REGION OF THE EGF RECEPTOR FUNCTIONS AS 
AN ACTIVATION DOMAIN 
 
INTRODUCTION 
 
  The 38 residue juxtamembrane (JM) region of the EGF receptor contains 
a variety of signaling and sorting motifs.  There are two sites of threonine 
phosphorylation within the JM region (Figure1).  T654 is defined as a protein 
kinase C (PKC) phosphorylation site and T669 a mitogen-activated protein 
(MAP) kinase site (Davis 1988; Takishima, Griswold-Prenner et al. 1991).  T654 
and T669 are phosphorylated with inhibitory consequences for kinase activity 
(Heisermann, Wiley et al. 1990; Welsh, Gill et al. 1991).  Heisermann et al (1990) 
showed that mutation of T669 in full-length receptor resulted in decreased 
endocytosis and tyrosine phosphorylation of cellular substrates.  Moreover, 
Welsh et al. (1991) demonstrated that not only is phosphorylation of T654 
required for TPA-mediated attenuation of EGF-induced tyrosine phosphorylation 
of cellular substrates, but T654 is also required for attenuation of morphological 
changes in NR6 cells ectopically expressing wild-type or T654A EGF receptors.  
In this case, TPA-induced lamellopodia formation was more extensive and rapid 
in cells containing the T654A mutant receptor.   
Four motifs for receptor sorting have been defined in the JM region 
(Figure 1).  Two basolateral sorting motifs are present and encoded by either a 
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dileucine motif  (L658-L659) or a PXXP motif (P667-P670) (He, Hobert et al. 
2002).  A lysosomal sorting signal has been defined (L679-L680) (Kil, Hobert et 
al. 1999; Song Jae Kil 2000), as well as a tripartite nuclear localization signal 
(R645-R647, R651-R653, R656-R657) (Hsu and Hung 2007).   
In addition to sorting motifs, a polybasic region (R645-Q660) within the JM 
has been proposed to modulate the activity of the kinase by acting as an 
‘electrostatic engine’ (McLaughlin, Smith et al. 2005).  Under basal conditions, 
this model predicts that the polybasic region of the JM electrostatically interacts 
with the plasma membrane (PM).  Upon ligand-induced receptor dimerization, 
transient increase in intracellular calcium leads to both reduction of electrostatic 
attractions as well as an increase in calmodulin levels.  Peptide studies have 
demonstrated that the JM interacts with lipid vesicles and that calmodulin, which 
associates with the EGF receptor JM, competitively inhibits JM peptide 
interaction with lipid vesicles (McLaughlin, Smith et al. 2005).  The electrostatic 
engine model predicts that the interaction of the JM polybasic region with the PM 
is autoinhibitory and that the calcium/calmodulin-induced dissociation of the JM 
from the PM leads to autophosphorylation of the receptor.   
In previous studies using large deletion mutations, a portion of the JM 
region was required for kinase activation (Thiel and Carpenter 2007).  Thus, the 
JM region of EGFR plays an activating role in the control of kinase activity and 
this contrasts with the autoinhibitory function described for JM regions of other 
RTKs, such as EphB2 and Flt3 (Hubbard 2004).  The conventional mechanism of 
JM-mediated tyrosine kinase autoinhibition is postulated to be due to the steric 
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hindrance of the nucleotide binding site by the JM region.  This mode of 
autoinhibition is relieved upon phosphorylation of tyrosine residues within the JM, 
resulting in the movement of the JM away from the ATP-binding site.   
In this chapter, I define the minimal JM activation domain (JMAD) using 
alanine scanning mutagenesis, and evaluate reported lung cancer mutations in 
this region for their influence on EGFR activity.  I also discuss a crystal structure 
of the EGFR TKD that contains the entire JM region.  This structure, produced by 
the Lemmon laboratory, illustrates the key interactions responsible for JMAD 
function in TKD activation, and suggests structural mechanisms for activation of 
EGFR by JM mutations in non-small cell lung cancer (NSCLC).   
 
RESULTS 
 
Scanning Alanine Mutagenesis of the EGF Receptor Juxtamembrane Region. 
 Previously published data showed that deletions in the JM region abolish 
both autophosphorylation of an intracellular domain (ICD) construct and EGF-
induced activation of intact EGFR overexpressed in Cos-7 and NIH3T3 cells, 
respectively (Thiel and Carpenter 2007).  Deleting residues 645-662 or 645-676 
of the JM region reduced ICD autophosphorylation in cells by ~95%.  Thiel and 
Carpenter proposed that these deletions indicated the presence of an activation 
domain within the JM region. 
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Figure 1.  Schematic of EGF Receptor JM Sorting Sequences.  Domains and 
regions of the EGF receptor are indicated.  The residues comprising the JM are 
numbered 645-682 and the PKC and MAPK phosphorylation site T654 and T669 are 
shown in green.  Receptor sorting sequences are aligned with the JM sequence.   A 
polybasic region extends from R645-R667.    
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JM residues 645-671 are absent from crystal structures of the EGFR TKD, 
which utilize constructs beginning at residue 672 (Stamos, Sliwkowski et al. 
2002; Wood, Truesdale et al. 2004; Zhang, Gureasko et al. 2006).  To determine 
which residues within the JM region contribute to tyrosine kinase activation, I 
employed scanning alanine mutagenesis of the 38 residue region in the context 
of a Flag epitope-tagged ICD construct (Figure 2A).  Since Thiel and Carpenter 
previously showed that mutating K721 (thus abrogating ATP-binding) abolished 
in vivo tyrosine autophosphorylation of EGFR ICD constructs, this argues that 
measurement of phosphotyrosine incorporation into the ICD reflects intrinsic 
kinase activity levels.  Therefore, the influence of mutations on ICD 
autophosphorylation only reflects the effects on TKD activation.  Indirect effects 
that arise from mutating JM trafficking motifs will not complicate the interpretation 
of these ICD studies as they might in studies of the intact receptor (Kil, Hobert et 
al. 1999; Song Jae Kil 2000; Lin, Makino et al. 2001; He, Hobert et al. 2002).   
Of the 36 alanine substitutions made in the JM region, 19 led to a 
significant reduction (≥50%) in ICD tyrosine phosphorylation (Figure 2B).  Fifteen 
of these ‘sensitive’ positions are located in the C-terminal portion of the JM 
(Figure 2B, Figure 3), between residues 664 and 682.   This is within a region of 
the JM encoded by exon 18 (which also encodes a portion of the N-lobe of the 
kinase domain).  Within this sequence, T669 (a known MAP kinase 
phosphorylation site: see above) is the only site at which alanine substitution 
does not impair kinase activity.  Interestingly, four of the loss-of-function 
mutations are either similar (L664A, V665A) or identical (P675A, L680A) to 
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changes present in the JM region of ErbB-3 (Figure 2A), a member of the EGFR 
family having an inactive tyrosine kinase domain (Guy, Platko et al. 1994).  The 
boundary between exon 17 and exon 18 is conserved in all 4 ErbB receptors, 
and the four receptors share more identity in the part of the JM region encoded 
by exon 18 than by exon 17 (Figure 2A). 
 
Analysis of JM Mutations in Full-Length EGFR. 
Three conservative JM mutations that span the entire JM region were analyzed 
in full-length EGFR: V650A, V665A, and L680A (Figure 2C).  Also, a catalytically 
inactive K721R EGFR was included to establish a baseline for loss-of-function.  
V650A was chosen as a control for replication of the ICD data in full-length 
receptor because the level of tyrosine phosphorylation of the mutant ICD was 
equivalent to that of wild-type ICD (Figure 2B, Figure 3). Each EGFR mutant was 
transiently expressed in NIH3T3 cells, and receptor tyrosine phosphorylation in 
the absence and presence of EGF at Y1173, a known major autophosphorylation 
site (Downward, Waterfield et al. 1985), was measured by western blotting.  The 
V650A mutant resembles wild-type EGFR in EGF-dependent 
autophosphorylation, consistent with the failure of this mutation to reduce ICD 
autophosphorylation (Figure 2C and 2B).  By contrast, autophosphorylation of the 
V665A or L680A mutants is significantly compromised, as in the ICD context 
(Figure 2B), and autophosphorylation of K721R EGFR is undetectable.  To 
control for the possibility that the results obtained with V665A and L680A EGFR 
mutants arise from impaired receptor trafficking to the cell surface, Alexafluor-
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conjugated EGF was incubated with 293 cells expressing each mutant or wild-
type EGFR and cell-surface fluorescence was assessed, using flow cytometry.  
All full-length receptor mutants were expressed on the cell surface at levels 
within 10% of the wild-type receptor (Figure 4A). 
 
Effects of Threonine Phosphorylation within the JM Region. 
The JM region contains two threonine residues that are phosphorylated in 
presumed regulatory feedback loops.  A previous study showed (Thiel and 
Carpenter 2007) that a phosphomimetic T654D mutation reduces ICD 
autophosphorylation by 50% compared to wild-type, whereas a T654A mutation 
elevates ICD phosphorylation (Figure 1B).    As shown in Figure 5A, a 
phosphomimetic T669D mutation also prevented ICD tyrosine phosphorylation, 
whereas a T669A mutation lead to elevated tyrosine phosphorylation compared 
to the wild-type ICD (Figures 5A and 1B).  Thus, phosphorylation of T669 is likely 
to exert the same influence on EGFR ICD activity as T654 phosphorylation, 
supporting a feedback mechanism for EGFR regulation by post-translational 
modification of T669 within the putative JM activation domain. 
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Figure 2.  Effect of Scanning Alanine Mutagenesis of the JM Region 
on Tyrosine Phosphorylation.  A. Schematic of full-length EGFR, with 
the transmembrane (TM), tyrosine kinase domain (TKD), and carboxy-
terminal (CT) regions marked.  The intracellular domain (ICD) construct 
includes the JM, TKD, and CT regions.  An alignment of JM region 
sequences across the human ErbB receptor family is shown, with the 
putative JM activation domain (JMAD) indicated.  B.  Scanning alanine 
mutagenesis of the JM region using ICD-flag constructs.  Cos-7 cells 
transiently expressing wild-type or mutated ICD-flag constructs were 
analyzed by Western blotting and densitometry for both phosphotyrosine 
content and flag-epitope expression.  The graph demonstrates the ratio 
of phosphotyrosine to flag expression for each construct relative to WT.  
Results represent the means of 2 experiments ± standard deviation.  C. 
Effect of JM alanine substitutions on tyrosine autophosphorylation of full-
length EGFR. NIH3T3 cells transiently expressing full-length EGFR with 
the indicated mutations were serum-starved and then treated (+) or not 
(-) with EGF for 10 min.  Cell lysates were subjected to SDS-PAGE and 
immunoblotting, detecting phospho-EGFR with anti-EGFR-pY1173 
(upper panel) and receptor levels with anti-EGFR (lower panel). 
 
Red Brewer et al.  Mol Cell 34:  641-651 (2009) 
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Figure 4.  Cell Surface Expression of Full-length EGF Receptor Mutants.  A. 293 
cells transiently expressing equivalent levels of N-terminal Flag-tagged WT, V665A, 
L680A, or V665M EGF receptors were treated with Alexa-EGF and analyzed using flow 
cytometry.  Geometric mean fluorescence values were collected and  Alexa-EGF 
binding was quantified. All mutants were normalized to WT. B. NIH3T3 cells transiently 
expressing equivalent levels of the constructs indicated above were stained with anti-
EGFR followed by Alexa488-labeled anti-mouse.  Cells were fixed with 4%PFA and 
mounted with glass coverslips.  Images were acquired using a Zeiss fluorescence 
microscope (see Supplemental Experimental Procedures). 
 
Red Brewer et al.  Mol Cell 34:  641-651 (2009) 
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Figure 5.  Effects of Mutations at JM Phosphorylation Sites.  A. Effect 
of a phosphomimetic mutation at T669 on ICD tyrosine Phosphorylation.  
The indicated flag-tagged ICD constructs were transiently expressed in 
Cos-7 cells.  Lysates were subjected to SDS-PAGE and immunoblotting 
as in Figure 1C, but using anti-Flag to normalize for ICD expression levels. 
B.  Regulation of constitutively active EGFR-L834R by a JM loss-of-
function mutant.  293 cells transiently expressing indicated ICD constructs 
were lysed and subjected to SDS-PAGE and immunoblotted with anti-
EGFR-pY-1173 and anti-Flag. 
 
Red Brewer et al.  Mol Cell 34:  641-651 (2009) 
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Regulation of L834R Tyrosine Phosphorylation by JM Mutation. 
Clinical studies of non-small cell lung cancer (NSCLC) have identified a 
number of mutations in the EGFR TKD that are associated with increased 
sensitivity to EGFR-targeted tyrosine kinase inhibitors (Sharma, Bell et al. 2007).  
Many of these mutations cause constitutive (ligand-independent) activation of the 
EGF receptor when studied in reconstituted cellular systems (Jiang, Greulich et 
al. 2005; Choi, Mendrola et al. 2007), and appear to do so by disrupting 
autoinhibitory interactions within the TKD (Zhang, Gureasko et al. 2006).  The 
L834R mutation, located in the kinase activation loop, is one of the most clinically 
frequent and well characterized examples.  To determine whether EGFR 
activation by such mutations requires JM-mediated interactions, I combined the 
L834R mutation with a loss-of-function JM region mutation (L680A).  A doubly 
mutated ICD construct containing L834R plus the JM L680A mutation was 
expressed in Cos-7 cells.  Figure 5B shows that kinase activation due to the 
L834R mutation was blocked by the L680A mutation, demonstrating that the 
activated kinase remains dependent on JM function. 
 
Activating EGFR JM Mutations in Non-Small Cell Lung Cancer. 
In addition to the TKD mutations, several publications have described 
relatively rare EGFR exon 18 JM point mutations in NSCLC patients (Chou, Chiu 
et al. 2005; Tsao, Sakurada et al. 2005; Pallis, Voutsina et al. 2007).  However, 
the impact of these mutations on receptor activity was not assessed, and in some 
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cases normal patient tissue was not examined for the presence of the mutation.  
Thus, the relationship of these mutations to NSCLC is currently not clear.   
To determine whether these patient-derived JM mutations effect receptor 
kinase activity, equivalent mutations were made in ICD constructs and expressed 
in Cos-7 cells (Figure 6A).  The L834R mutant was also analyzed as a positive 
control.  Most of the patient-derived JM mutations (L664P, P667S, L668P, 
P670L/S, and N676D) reduced ICD autophosphorylation, either suggesting that 
they may not be relevant in NSCLC, or that mutation results in misfolding of the 
ICD (Figure 6A).  However, two mutations (V665M and L679F) significantly 
increased ICD tyrosine phosphorylation, to levels similar to those produced by 
the L834R mutation. 
 I next introduced one gain-of-function mutant, V665M, which was not 
included in previously published crystal structures, as well as two loss-of-function 
mutants, L668P and P670L, into full-length EGFR, and measured tyrosine 
phosphorylation of transiently expressed receptor in NIH 3T3 cells treated or not 
with EGF (Figure 6B and 6C).  Consistent with the ICD studies, the V665M 
mutation promotes ligand-independent EGFR autophosphorylation such that 
V665M EGFR is as phosphorylated in the absence of EGF as the activated wild-
type receptor in the presence of EGF.  This effect cannot be explained by 
differences in cell-surface expression of the mutant compared to wild-type 
receptor (Figure 4A).  Thus, the V665M mutation resembles other activating 
NSCLC mutations in its effects on full-length EGFR (Jiang, Greulich et al. 2005; 
Choi, Mendrola et al. 2007), suggesting that it could represent an oncogenic JM 
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mutation with relevance in NSCLC.  By contrast, the L668P mutation reduced 
EGF-induced receptor autophosphorylation, consistent with its effect in the ICD 
context.  These biochemical data suggests that for the L668P mutant NSCLC 
tumor, the observed disease may have been due to an EGF receptor-
independent mechanism.  In the presence of EGF, the P670L mutant was 
tyrosine phosphorylated at a level equivalent to that of wild-type receptor (Figure 
6C).  This result was inconsistent with the observed loss of autophosphorylation 
in the ICD system, suggesting a possible effect of this proline substitution on ICD 
stability (Figure 2B and 3). 
 
V665M EGFR Promotes Cellular Transformation and Tumorigenesis. 
The hallmarks of cellular transformation in culture are growth in the 
absence of serum, loss of contact inhibition, and anchorage-independent growth 
(Hanahan and Weinberg 2000; Ruddon 2007).  To evaluate the proliferative and 
oncogenic potential of the V665M mutation, I tested NIH3T3 cells stably 
expressing wild-type, V665M, L834R, or D813A (catalytically-inactive) EGFR for 
colony formation in soft agar in the absence and presence of EGF.     In the 
presence of EGF the V665M EGFR mutant supports anchorage-independent 
growth more effectively than the wild-type receptor (Figure 7A).  Moreover, cells 
expressing V665M EGFR formed more colonies following EGF addition than 
cells expressing the well-described NSCLC mutant L834R.  Neither the V665M 
nor the L834R mutant-expressing NIH 3T3 cells formed a substantial  
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Figure 6.  Effects of Clinically-Observed JM Mutations on EGFR 
Activity.  A. The noted clinically-observed JM mutations were introduced 
into the Flag-tagged EGFR ICD.  The resulting constructs were 
transiently expressed in Cos-7 cells, and ICD autophosphorylation was 
assessed as described in Figure 1.  B. and C. The V665M, L668P, and 
P670L mutations were also introduced into full-length EGFR, and the 
influence on EGF-dependent (+) and EGF-independent (-) EGFR 
autophosphorylation was assessed as described for Figure 1C.  The 
K721R inactivating mutation was included as a negative control (C). 
 
Red Brewer et al.  Mol Cell 34:  641-651 (2009) 
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number of colonies in the absence of EGF, although they formed approximately 2 
and 4 times more colonies than untreated NIH 3T3 cells expressing wild-type 
receptor, respectively (Figure 7A).  The NIH 3T3 parental cell type was selected 
for its low level of endogenous EGF receptor (~5,000 receptors/cell) compared to 
other cell types that typically express moderate levels of EGF receptor, as well as 
other ErbB family members. Importantly, cells expressing the vector only form an 
equivalent number of colonies to wild-type expressing cells in the absence of 
EGF, consistent with the requirement of EGF receptor tyrosine kinase activity for 
proliferative response.   
In collaboration with Dr. Ambra Pozzi, I sought to determine whether the 
observed increase in anchorage-independent growth produced by the V665M 
EGFR in vitro reflects oncogenic transformation in vivo.  Dr. Pozzi performed 
subcutaneous injections of NIH3T3 cells stably expressing equivalent levels of 
wild-type or V665M EGFR into nude mice.  Three months after injection, cells 
expressing V665M EGFR formed more (and larger) tumors than cells expressing 
wild-type EGFR, regardless of the number of cells injected (Figure7B).  These 
results indicate that the JM activation domain is a significant factor in the 
regulation of EGF receptor kinase activity at the biological, as well as 
biochemical, level.   
 Due to the increase in oncogenic potential mediated by the V665M 
mutation (Figure 7), attempts to understand potential signaling differences 
between the wild-type and V665M mutant EGF receptor were made by assessing 
both EGFR tyrosine autophosphorylation and Stat-3 activation.  Recent data 
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suggests that EGF receptor mutations within the TKD of EGF receptor can 
mediate constitutive Stat-3 activation via an IL-6 autocrine pathway in different 
NSCLC lines, the end result of which is increased cell survival (Haura, Zheng et 
al. 2005; Gao, Mark et al. 2007).   293 cells transiently expressing EGF receptor 
containing the V665M mutation resulted in an increase in basal and ligand-
induced Stat-3 activation compared to wild-type receptor (Figure 8).  No 
significant differences were observed in phosphorylation of Tyr 992, 1045, or 
1068.  These data are consistent with a V665M mutant-dependent pStat-3, which 
in other systems is reported to result in a prosurvival phenotype.   
 
Mechanism of EGFR Activation by the V665M Mutation. 
Zhang et al. (2006) described a mechanism for activation of the EGFR 
TKD in which the C-lobe of a ‘donor’ monomer contacts the N-lobe of an 
‘acceptor’ monomer in the asymmetric dimer (Figure 11B).  The resulting 
conformational changes in the acceptor monomer lead to its allosteric activation.  
I took advantage of mutations (Zhang, Gureasko et al. 2006) that force receptor 
molecules to act solely as donor monomers (I682Q) or acceptor monomers 
(V924R) to determine whether the V665M-mutated EGFR ICD functions more 
effectively than wild-type as donor, acceptor, or both.   
 
 
46 
 
 
  
 
Red Brewer et al.  Mol Cell 34:  641-651 (2009) 
 
47 
 
 
  
Figure 7.  EGFR-V665M is Transforming in NIH3T3 Cells.  A. NIH3T3 cells 
stably expressing the indicated wild-type or mutated forms of EGFR (or pBabe-
puro vector only) were seeded at a density of 8x103 cells per well in a standard 
colony forming assay (see Experimental Procedures).  Cells were incubated for 
3 weeks in the absence or presence of 50ng/ml EGF, and colonies were then 
counted.  The results are presented as the means of 3 experiments ± standard 
deviation.  To control for possible differences in expression level of the mutants, 
NIH3T3 stably expressing each mutant were lysed and analyzed by SDS-PAGE 
and immunoblotting with anti-EGFR.  B.  Upper panel: Example of tumors 
isolated from nude mice 3 months after s.c. injection with NIH3T3 cells stably 
expressing wild-type or V665M EGFR or the pBabe-puro vector.  Lower panel: 
Volumes of tumors derived from the cells indicated above were evaluated 3 
months after s.c. injection.  Open circles represent single mice with a total of 4 
mice per cell type analyzed.  Cells for xenograft assay created by Monica Red 
Brewer.  Subcutaneous injection, tumor collection, and measurement by  Ambra 
Pozzi. 
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Figure  8.  The EGF Receptor V665M Mutation Mediates 
Constitutive Activation of Stat-3.   293 cells transiently expressing 
either wild-type or mutant EGF receptor were serum-starved an 
treated or not  for the indicated times (in minutes).  Cells were then 
lysed and lysates resolved by SDS-PAGE.  Membranes were western 
blotted with the indicated antibodies. 
Red Brewer et al.  Unpublished data (2009) 
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The donor ICD was myc-tagged, and the acceptor ICD was FLAG-tagged, 
and when expressed alone, neither ICD is autophosphorylated (Figure 9, lanes 3 
and 4); however, substantial activity was detected when the two were co-
expressed (lane 5).  Lanes 8-10 (Figure 9) demonstrate that increased ICD 
autophosphorylation compared to the wild-type level is observed when the 
V665M mutation is present in the acceptor monomer (V924R/V665M), regardless 
of whether it is co-expressed with the I682Q donor or the doubly-mutated 
(I682Q/V665M) donor.  When the V924R/V665M acceptor was expressed 
without a donor monomer (Figure 9: lane 7), there was no activation, indicating 
that the large increase in activation observed in lanes 9 and 10 requires donor: 
acceptor interaction.  In contrast, coexpression of an I682Q/V665M donor with a 
V924R acceptor (lane 8) did not increase tyrosine phosphorylation compared to 
the control (lane 5).   
These data establish that the V665M JM mutation enhances the capacity 
of the ICD to act as an acceptor monomer, but does not greatly influence its 
ability to function as a donor.  This is consistent with the previous finding that an 
intact JM region is required for the EGFR ICD to function as an acceptor in the 
asymmetric dimer (Thiel and Carpenter 2007).  The V665M mutation seen in 
NSCLC enhances JM function in this context. 
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Figure 9.  The V665M Mutation Must be Present in the Acceptor 
Molecule to Activate EGFR.  ICD constructs containing mutations that limit 
them to functioning only as a donor (I682Q) or acceptor (V924R) in the 
asymmetric TKD dimer were used to assess the mechanism by which the 
V665M mutation activates EGFR.  The noted combinations of ICD 
constructs were coexpressed in 293 cells as indicated, and lysates were 
subjected to SDS-PAGE and immunoblotting for phospho-EGFR (with anti-
EGFR-pY1173) and for protein levels with anti-Myc, and anti-Flag as 
appropriate.  Autophosphorylation levels are greater than wild-type (lane 2) 
only when the V665M mutation is present in the acceptor TKD (lanes 9 and 
10). 
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Sensitivity of the EGF receptor mutant V665M to Small Molecule Inhibition 
Due to the novel nature of receptor activation by the juxtamembrane 
activation domain (JMAD), sensitivity of the activating mutant V665M to the 
clinically available small molecule inhibitor erlotinib was assessed.  Erlotinib, also 
known as Tarceva, is a reversible TKI that binds to the open conformation of the 
tyrosine kinase domain within the ATP-binding pocket.  293 cells transiently 
expressing either wild-type EGF receptor, the activating JM mutant V665M, and 
the erlotinib-sensitive L834R mutant, were treated with increasing concentrations 
of erlotinib in the absence or presence of EGF and assessed for inhibition of 
receptor activation by phosphotyrosine western blot (Figure 10).  These data 
show that the V665M mutant does not demonstrate increased sensitivity to 
erlotinib compared to wild-type EGF receptor.  Complete loss of tyrosine 
phosphorylation of the wild-type receptor and V665M mutant is observed at a 
dose of 1uM erlotinib.   
 
DISCUSSION 
Crystallographic studies together with mutagenesis and biochemical data 
indicate that for several RTKs (c-Kit, EphB2, and Flt3) the intracellular JM region 
plays an autoinhibitory role, sterically hindering substrate access to the 
nucleotide binding pocket (Wybenga-Groot, Baskin et al. 2001; Chan, 
Ilangumaran et al. 2003; Griffith, Black et al. 2004).  In these RTKs, 
phosphorylation of key tyrosines within the JM region results in a conformational  
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Figure 10. The Non-Small Cell Lung Cancer Mutation 
EGFR-V665M Shows no Increase in Sensitivity to 
Erlotinib.  NIH3T3 cells transiently expressing either WT 
EGFR, EGFR-V665M, or the activating EGFR-L834R were 
serum starved and either treated or not with the indicated 
concentrations of erlotinib (0.01, 0.1, or 1.0 uM) for 2 hours 
followed by 50 ng/mL EGF for 10 minutes as indicated.  
Lysates were subjected to SDS-PAGE and western blotted 
with anti-EGFR-pY1173 followed by EGFR antibody.   
 
Red Brewer et al.  Unpublished data (2009) 
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shift that reverses the autoinhibition - leading to kinase activation (Binns, Taylor 
et al. 2000; Mol, Lim et al. 2003).   
In contrast, I show here that the JM region (residues 664-682) of the EGF 
receptor exhibits an activating rather than autoinhibitory role.  Unlike the direct 
occlusion of the kinase active site seen in JM-mediated autoinhibition of other 
RTKs (Hubbard 2004), the JM-mediated activation of the EGF receptor occurs in 
an allosteric fashion.  Alanine substitutions at most positions in the C-terminal 
half of the JM region (encoded by exon 18) lead to a loss of kinase activity.  I 
have termed this part of the JM region the JM activation domain (JMAD).   
Alanine substitutions at the N-terminal portion of the JM encoded by exon 
17 result in a greater degree of variability in terms of tyrosine phosphorylation 
when compared to wild-type ICD.  In general, the N-terminal substitutions do not 
result in loss of ICD tyrosine phosphorylation.  Only two alanine substitutions in 
this portion of the JM, R646A and R647A, resulted in a severe loss (<25%) in 
tyrosine phosphorylation (Figure 2B and 3).  While the loss-of-function observed 
for these two alanine mutants could result from misfolding, Jura et al. (2009) 
have proposed a model that may explain the effect of R646A and R647A on 
tyrosine phosphorylation.  Using structural modeling of the EGF receptor 
transmembrane domain with existing structural information regarding the TM 
helical dimers of ErbB-2, the authors propose that R647 lies at the interface of 
the plasma membrane (PM) and cytosol and electrostatically interacts with the 
negatively charged head groups of the PM.  The positioning of the TM helices 
and N-terminal residues of the JM are hypothesized to be of paramount 
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importance in the spatial orientation of the asymmetric TKD dimer, in which an 
approximate distance of 18-20 Å is required for proper asymmetric alignment and 
activation of the TKDs.   
This model provides an explanation for the loss-of-function observed with 
the R647A mutant.  In this case, disrupting the electrostatic interaction of this 
basic residue with the phosphates of the PM could certainly have an effect on 
positioning of the ICDs.  However, alignment of the ErbB-2 TM sequence with 
EGFR R647 shows that this arginine residue is not conserved in ErbB-2, but is a 
glutamine residue, thus suggesting that the overlay of ErbB-2 and EGFR TM 
domain provided by modeling may not provide precise information about their 
spatial distributions, and that there may be slight differences in the distances 
between the C-terminal TM residues achieved by each of these proteins.  My 
mutational data also implies a role for R646 in this model of spatially controlled 
TKD dimerization.   Whether R646 plays an equivalent role with R647 by 
electrostatic interaction with the PM is unclear, but would seem quite plausible.   
In an effort to understand how the JM region exerts its positive influence 
on EGFR activation, I collaborated with the Lemmon laboratory to crystallize a 
form of the EGFR TKD that extends from residue 645 to 998 (EGFR645-998), and 
includes the entire JM region (Red Brewer, Choi et al. 2009).  Previous 
crystallographic studies of EGFR TKD have utilized protein that lacks residues 
645-671 (Stamos, Sliwkowski et al. 2002; Wood, Truesdale et al. 2004; Zhang, 
Gureasko et al. 2006; Yun, Boggon et al. 2007).  The best crystals obtained by 
the Lemmon group diffracted to 2.8Å resolution and were acquired using a form 
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of EGFR645-998 with an inactivating K721M mutation in the kinase active site.  
Members of the Lemmon Laboratory are responsible for generation of Figures 11 
and 12 within this Discussion and have also contributed to the interpretation of 
the structural information herein.  Please refer to Red Brewer et al. (2009) for a 
more complete account of the structural data presented in this Discussion. 
 EGFR645-998(K721M) formed the same asymmetric dimer as that reported 
previously (Figures 11A, 12B) for active conformations of the EGFR TKD 
(Stamos, Sliwkowski et al. 2002; Zhang, Gureasko et al. 2006; Yun, Boggon et 
al. 2007), and the ErbB4 TKD in both active (Qiu, Tarrant et al. 2008) and 
inactive (inhibitor-bound) states (Wood, Shewchuk et al. 2008).  In this dimer, the 
C-lobe of the donor monomer (yellow) abuts the N-lobe of the acceptor monomer 
(green).  The binding surface on the acceptor N-lobe includes contributions from 
the αC helix, the β4/β5 loop, and an N-terminal extension of the N-lobe (marked 
in Figure 11B) that includes part of the JM region.  Rearrangement of these 
structural elements upon interaction with the donor C-lobe leads to allosteric 
activation of the acceptor (Zhang, Gureasko et al. 2006).  Defined electron 
density begins at R653, so this structure lacks only the sequence 
645RRRHIVRK652 that immediately follows the transmembrane domain.  The 
extended JM region of the acceptor monomer in EGFR645-998 appears to ‘cradle’ 
the C-lobe of the donor (Figure 11A).  The interactions mediated by the JMAD as 
shown in this structure are consistent with the results of the alanine scanning 
data in Figure 2B.   
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 Even though most of the donor/acceptor interactions seen in previous 
active structures (Zhang, Gureasko et al. 2006) are maintained in the EGFR645-
998(K721M) dimer (Figure 11A), it is apparent that the K721M TKD itself adopts 
an inactive-like conformation (Wood, Truesdale et al. 2004; Zhang, Gureasko et 
al. 2006).  The K721M-mutated acceptor TKD in Figure 11A maintains an 
inactive-like conformation despite retaining nearly all interactions with the donor 
that normally promote allosteric activation.  This is evident from the slightly 
different orientations between the N- and C-lobes of each monomer in the 
structures shown in Figures 11A and 11B.  The fact that EGFR645-998(K721M) can 
form the asymmetric dimer shown in Figure 11 while adopting an inactive 
conformation suggests that the JM region plays a critical role in stabilizing this 
normally-activating mode of TKD association.  An analogous situation can be 
inferred for ErbB4, where an inhibitor-bound inactive conformation crystallized as 
an asymmetric dimer (as in Figure 11) when part of the JM region was included 
in the protein (Wood, Shewchuk et al. 2008), but not when the JM region was 
absent (Qiu, Tarrant et al. 2008).  Additionally, the requirement for the JM in 
stabilizing the asymmetric dimer is supported by biochemical evidence.  The TKD 
alone is reported to exist mostly in a monomeric state at 150uM, while TKDs with 
intact JM regions exist predominantly as dimers, based on size exclusion 
experiments employing static light scattering (Jura, Endres et al. 2009).   
Most of residues 664-671 (T669 is an exception) in the JM region of the 
acceptor (green) make contacts with the C-lobe of the donor (yellow), as shown 
in Figure 11C.  Consistent with this, alanine substitution at these positions had a  
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Figure 11.  The Acceptor JM Region ‘Cradles’ the C-lobe of the 
Donor in an Asymmetric TKD Dimer.  A. Cartoon representation of the 
crystal structure of EGFR645-998 harboring an inactivating K721M 
mutation.  The TKD forms a crystallographic dimer that closely resembles 
the asymmetric TKD dimer seen for protein that lacks the complete JM 
region (Takishima, Griswold-Prenner et al. 1991; Zhang, Gureasko et al. 
2006).  The ‘Acceptor’ TKD is colored green, and ‘Donor’ TKD yellow.  
The N-lobe and C-lobe of donor and acceptor molecules are labeled, as 
are key helices in the donor C-lobe.  Helix αC in the acceptor N-lobe is 
also marked.  The N-terminal part of the JM region of the acceptor 
‘cradles’ the donor C-lobe.  The short N-terminal a-helix of the acceptor 
(residues 654-663) projects away from the donor, and makes no direct 
contacts.  B. Structure of the active asymmetric dimer of the wild-type 
EGFR TKD lacking residues 645-671 from the JM region (PDB ID 2GS6), 
from Zhang et al. (2006).  Features labeled in A are also labeled for this 
structure.  C. Detailed view of side-chains in the acceptor JM region 
(green) that make contact with the C-lobe of the donor TKD.  The 
orientation for this figure is shown in the cartoon representation in the 
inset, and the region shown is boxed.  All side-chains present in the 
crystal structure from T654-R681 are shown.  Those side-chains colored 
light grey could be replaced by alanine with no effect on ICD activity in 
Figure 1B (including T669).  Side-chains colored green could not be 
replaced by alanine without significant loss of activity.  Residue labels 
boxed in green correspond to the N-terminal half of the JM activation 
domain, where alanine substitutions have the greatest effect.  Note that 
the N-terminal helix of the acceptor structure makes no direct contact 
with the donor.  Structure by Sung Hee Choi, Diego Alvarado, Katarina 
Morevcevic, and Mark Lemmon. 
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strong inhibitory effect on EGFR ICD activation (Figure 2B).  Residues 664- 671 
of the acceptor JM region occlude 488Å2 on the donor C-lobe surface.  
Alanine substitutions at L664, V665, L668 or S671 are predicted to reduce 
van der Waal’s interactions between the JM region and donor C-lobe (or 
hydrogen bonding interactions in the case of S671).  Replacing E666 with 
alanine will abrogate electrostatic interactions with R949 in helix I of the donor C-
lobe.  Alanine substitution at P667, P670 or G672 could change local structure 
(and/or disrupt van der Waal’s interactions) and thereby weaken JM interactions 
with the donor C-lobe.  The data in Figure 2B show that each of these changes 
impairs EGFR ICD autophosphorylation as the structure generated by the 
Lemmon laboratory would predict.  Of equal importance, where Figure 2B 
indicates no (or little) inhibitory effect of alanine substitution (T654-E663, and 
T669), Figure 11C shows that the side-chains in the JM region are not in direct 
contact with the donor C-lobe.  These ‘insensitive’ side-chains are colored light 
gray in Figure 11C. 
 The α-helix at the N-terminus of the acceptor JM region (residues 653-
663) makes no direct contact with the donor C-lobe.  Its axis is approximately 
perpendicular to the C-lobe surface in Figures 11A and C.  This helix is part of a  
reported binding site for calmodulin that encompasses residues 645-660 (Martin-
Nieto and Villalobo 1998).  The independence of this N-terminal helix in the 
structure presented here, and the disorder of the polybasic region that precedes 
it (residues 645-653), argue that the reported interactions of the EGFR JM region 
with calmodulin (Martin-Nieto and Villalobo 1998) and with negatively-charged 
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membrane surfaces (McLaughlin, Smith et al. 2005) might occur in concert with 
the cradling of the donor C-lobe seen here.  Thus, proposed modes of JM-
mediated EGFR regulation that involve these interactions (McLaughlin, Smith et 
al. 2005) may occur in parallel with the JM contributions to donor/acceptor 
interactions seen in Figure 11C.  
These predictions are supported by structural modeling data from the 
Kuriyan group.  In their model, dimerization of receptors results in the antiparallel 
association of JM-A (or exon 17) alpha helices.   Jura et al. (2009) show, using 
molecular modeling, that the antiparallel alpha helices are created by residues 
652-663 in the dimer state.  These residues immediately precede the JMAD and 
demonstrate polarity whereby one ‘face’ of a donor helix is composed mainly of 
acidic residues which are thought to interact with the negatively charged plasma 
membrane, and the opposing face of an acceptor helix is composed of basic 
residues which face the kinase.  Whether or not calmodulin recognizes this 
predicted anti-parallel helical structure is not known. 
 Phosphorylation of T654 and T669 were reported to provide mechanisms 
of negative feedback regulation of EGF receptor tyrosine kinase activity                         
(Davis 1988; Heisermann, Wiley et al. 1990).  Biochemical evidence supports 
roles for modification of these residues in the regulation of tyrosine kinase activity 
(Figure 5) (Thiel and Carpenter 2007).  Structural explanations for this mode of 
negative feedback regulation are not as straightforward.  Neither the T654 nor 
the T669 side-chain of the acceptor TKD is involved in direct interactions with the 
donor TKD, so substitution (or phosphorylation) does not reflect a loss of JM-
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mediated interactions between TKD domains.  In the case of T669 
phosphorylation, the observed inhibition could result from changes in JM 
structure or stability when a phosphate group is added, globally disrupting JM-
mediated interactions.  Phosphorylation of T669 within the JMAD is predicted to 
disrupt its local structure, resulting in inhibition of EGFR activity by reducing the 
strength of acceptor/donor interactions.  For T654 phosphorylation, the structure 
presented here does not suggest a clear possibility.  Interestingly, alignment of 
EGFR (ErbB-1) and ErbB-3 JM sequences (Figure 2A) shows that the EGFR 
T669, which is conserved in both ErbB-2 and -4, is an aspartate in ErbB-3, 
consistent with reports that ErbB-3 has little or no kinase activity (Guy, Platko et 
al. 1994). 
Examination of the interface between the JM region of the acceptor and C-
lobe of the donor (Figure 11C) provides a possible structural basis for the EGFR 
activation by the V665M and L679F mutations found in NSCLC patients.  The 
side-chain of V665 projects into a cavity on the surface of the C-lobe that is lined 
by aliphatic portions of Q788 and Y789 from helix E and Q825 from the β7/β8 
loop (between the catalytic loop and activation loop of the TKD).  The V665 side-
chain does not fill this cavity (Figure 12A).  However, substituting V665 with a 
methionine – as modeled by members of the Lemmon laboratory in the right-
hand panel of Figure 12A – would fill the cavity completely, and is likely to 
stabilize the association of the acceptor’s JM region with the donor C-lobe at this 
location.  It is interesting to note that substitution of V665 with an alanine results 
in loss of tyrosine phosphorylation (Figure 2B and C).  A second reported clinical 
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mutation, L679F, was also modeled.  Mutation of L679 to phenylalanine could 
improve packing of the JM  region with a PQPP sequence between helices αG 
and αH in the C-lobe of the donor (Figure 12B).   
By solving the crystal structure of an EGFR TKD with its JM region intact, 
the Lemmon group showed that most of the 19-amino acid JMAD (residues 664-
682) of an acceptor in the asymmetric TKD dimer makes contact with the C-lobe 
of the donor.  Consistent with both biochemical and structural data, the most 
straightforward explanation for how the JMAD contributes to EGFR activation is 
that it stabilizes formation of the asymmetric dimer, thus promoting allosteric 
activation of the acceptor TKD.  Supporting biochemical evidence shows that the 
addition of the JM results in a 67-fold increase in kinase activity in solution 
compared to wild-type ICD (Jura, Endres et al. 2009).  This might reflect JMAD-
stabilized formation of head-to-tail TKD polymers similar to those seen in 
crystals.     
Identification of an important regulatory domain within the ICD but outside 
the TKD proper is of particular significance, because regions outside the kinase 
domain are rarely examined for mutations in clinical screens (Sharma, Bell et al. 
2007).  Where broader screens have been performed, a limited number of rare 
JM mutations in clinical tumor samples have been reported, but not 
characterized.  I found that two of these previously reported clinical EGFR JM 
mutations (V665M and L679F) activate the receptor.  L679F is tumor-specific, as 
the mutation was not found in normal tissue (Pallis, Voutsina et al. 2007).  
However, whether or not the V665M mutation is tumor-specific is not known.  In 
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both cases, the degree of EGFR activation is similar to that seen for well-
characterized oncogenic mutations (such as L834R) in the TKD itself (Sharma, 
Bell et al. 2007).  Biochemical studies and structural arguments suggest that the 
V665M mutation stabilizes acceptor/donor interactions.  The existence of such a 
clinically-observed mutation within the JMAD that I also show to be activating and 
transforming highlights the biological importance of this domain in regulating the 
EGF receptor kinase activity and cellular responsiveness.  This activation domain 
is encoded by the same exon as a significant portion of the N-lobe of the TKD, 
and could be considered as a part of the TKD proper. 
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Figure 12.  Mechanism of Activating JM Mutations.  A. Contacts 
between the acceptor JM domain and donor C-lobe are shown with 
the V665 side-chain represented as space-filling spheres.  The V665 
side-chain fails to fill a cavity on the donor C-lobe formed by the side-
chains of Q788, Y789 and Q825.  However, as shown in the right-
hand panel, a methionine (red) at position 665 – modeled for this 
figure - would completely fill the cavity, increasing van der Waal’s 
contacts between acceptor and donor.  B. Similarly, the L679F 
mutation is likely to promote interactions between the JM region 
(green) and the donor C-lobe, as indicated by modeling a 
phenylalanine at this position.  Data by Sung Hee Choi, Diego 
Alvarado, Katarina Moravcevic, and Mark Lemmon 
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CHAPTER IV 
 
THE p97 AAA-ATPASE IS REQUIRED FOR LIGAND-DEPENDENT NUCLEAR 
LOCALIZATION OF EPIDERMAL GROWTH FACTOR RECEPTOR 
 
INTRODUCTION 
 
Nuclear localization of the EGF receptor is known to mediate cellular 
effects such as induction of iNOS and  cyclin D1 genes, which leads to increased  
cellular proliferation (Lala and Chakraborty 2001; Lin, Makino et al. 2001; Stacey 
2003; Lo, Hsu et al. 2005).  Evidence of nuclear localization of soluble EGF 
receptor exists as confocal and electron microscopy (EM) data, in both breast 
cancer cells and tumor tissue, as well as biochemical fractionation data (Lin, 
Makino et al. 2001; Lo, Hsu et al. 2005; Liao and Carpenter 2007).  The confocal 
and EM data show diffuse EGF receptor localized to the nuclear compartment 
without evidence of nuclear membrane involvement, while the biochemical data 
demonstrates nuclear receptor solubility by extraction of full length receptor using 
a detergent-free high salt buffer.  Nuclear full-length EGF receptor has been 
detected in numerous breast cancer cell lines, as well as in tissue samples from 
breast cancer patients (Lo, Xia et al. 2005).  Since it is not detectable in the 
nuclei of normal tissue, this implies a role in breast cancer tumorigenesis.  Also, 
nuclear EGF receptor in breast cancer tissue samples serves as a poor 
prognostic indicator compared to that of tissue in which EGF receptor is present, 
but not detected in the nucleus (Lo, Xia et al. 2005). 
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Trafficking of mature full-length EGF receptor to the nucleus has been 
shown to require the Sec61 translocon (Liao and Carpenter 2007).  The Sec61 
translocon is a trimeric complex consisting of α, β, and γ subunits(Osborne, 
Rapoport et al. 2005).  It is localized to the endoplasmic reticulum (ER) and early 
Golgi (Greenfield and High 1999).  The translocon exhibits bidirectional 
movement of proteins either from the cytosol into the ER, or by retro-
translocation of misfolded proteins or toxins from the ER to the cytosol (Osborne, 
Rapoport et al. 2005).  Nascent proteins are first translocated from the ribosome 
to the ER (through the translocon) to achieve proper conformation and 
glycosylation (Trombetta and Parodi 2003).  In the ER, if proper folding is not 
achieved, proteins are then retro-translocated from the ER to the cytosol, where 
they degraded by the proteasome (Trombetta and Parodi 2003).  The process of 
retro-translocation of misfolded proteins from the ER is known as ER-associated 
degradation (ERAD).  
Data by Liao and Carpenter (2007) describe how the Sec61 translocon, an 
endoplasmic reticulum (ER) - localized protein complex, mediates trafficking of 
activated cell surface EGF receptor to the nucleus. Retrotranslocation of mature 
EGF receptor by the Sec61 translocon is thought to provide a means by which 
the receptor is liberated from its lipid membrane environment. Liao and 
Carpenter (2007) report that association of mature EGF receptor with the Sec61β 
subunit of the translocon is observed 3 hours post ligand addition, and that the 
nuclear receptor is high-salt extractable.    Knockdown of the Sec61α subunit of 
the translocon results in loss of ligand-dependent nuclear localization of mature 
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EGF receptor.   These results are consistent with a novel trafficking pathway in 
which the Sec61 translocon may function to free membrane-bound receptor to 
allow for trafficking of soluble receptor to the nucleus. 
A central question in the Sec61-dependent mechanism of EGF receptor 
nuclear localization is how the Sec61-associated EGF receptor is ‘extracted’ or 
dislocated from the translocon.  A candidate protein that may supply the motive 
force for this dislocation is the AAA-ATPase p97, since it is known to be required 
for the dislocation of substrates from the ER and derlin translocons (Ye, Meyer et 
al. 2001; Ye, Shibata et al. 2004). 
P97, also known as valosin-containing protein (VCP) in mammalian 
systems and CDC48 in yeast, is a ubiquitous protein, comprising roughly 1% of 
the total cytosolic protein of a cell.  It is a member of the type II AAA (ATPases 
associated with a variety of activities), and  contains two AAA domains, also 
known as D1 and D2, which are responsible for nucleotide binding and hydrolysis 
(Wang, Song et al. 2004) (Figure 1).  Hydrolysis of γ-phosphates from an ATP 
molecule bound to a functional homohexameric p97 is thought to supply 
mechanical force to the substrates of the ATPase in processes such as ERAD 
(Wang, Song et al. 2004).  p97 participates in several different cellular processes 
in which its function appears to be governed by either its association with 
cofactors and/or ubiquitin chains of substrates.  Cofactors of p97, which operate 
as targeting subunits, are quite variable and do not appear to fall into one 
discrete functional category. Rather, in concert with p97, its cofactors mediate a 
wide variety of cellular functions that range from DNA damage repair (BRCA1  
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Figure 1.  Schematic of p97 with Structural-Functional Relationships 
Indicated.  The N-domain of p97 mediates interaction with protein substrates and 
cofactors.  The D1 domain mediates the formation of stable hexamers of p97.  The 
D2 domain binds and hydrolyses ATP.  Both D-domains contain Walker A and B 
motifs and SRH (second region of homology).  The Walker A and B motifs are 
traditionally described to mediate nucleotide-binding and hydrolysis, respectively.  
However, functional Walker motifs have only be described for the D2 domain.  
Likewise, a role for the SRH has been postulated in ATP hydrolysis.  The C-domain 
is tyrosine phosphorylated. 
 
Wang et al.  Journal of Structural Biology 146: 44-57 (2004) 
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and Wrn) and protein degradation (Ufd2 and Ufd3) to membrane trafficking 
(clathrin and syntaxin 1)(Dreveny, Pye et al. 2004).  With the exception of one 
cofactor, Ufd3, all known p97 cofactors are known to associate with the N-
domain of the ATPase (Zhao, Zhou et al. 2007).    
Besides functional regulation due to cofactor association, posttranslational 
modifications can also affect p97 function.  The prevalence of ubiquitin moieties 
on substrate proteins as well as the capacity of cofactors to mediate ubiquitin-
dependent processes, suggests that besides functioning as a protein trafficking 
chaperone, p97 can also orchestrate ubiquitin-dependent processes (Ye 2006).  
When not associated with a cofactor, p97 can weakly associate with polyubiquitin 
moieties through a ubiquitin binding site in its N-domain.  However, p97 is known 
to associate with cofactors that contain ubiquitin binding domains (such as Npl4 
and p47) as well as E3 ligases (such as Hrd1 and Gp78)(Ye 2006). 
Although p97 exhibits nucleo-cytoplasmic distribution, its yeast homologue 
Cdc48, is reported to localize to the cytosolic leaflet of the ER or the nucleus 
based on its tyrosine phosphorylation (Latterich, Frohlich et al. 1995; Madeo, 
Schlauer et al. 1998).  p97 was first reported to be tyrosine phosphorylated in 
response to T-cell receptor activation (Egerton, Ashe et al. 1992).  It has since 
been reported to be phosphorylated by Src as well as by activated Akt in 
response to phorbol ester, FGF, or EGF (Vandermoere, El Yazidi-Belkoura et al. 
2006; Li, Zhao et al. 2008).  Tyrosine phosphorylation of the penultimate Tyr 805 
in the C-domain is known to result in redistribution of the yeast homologue Cdc48 
to the nuclear compartment, suggesting a regulatory role for this modification in 
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subcellular localization (Madeo, Schlauer et al. 1998). Moreover, tyrosine 
phosphorylation of this residue is reported to abolish the ERAD-associated 
activity of p97 (Zhao, Zhou et al. 2007; Li, Zhao et al. 2008), adding yet another 
layer of regulatory complexity to the function of the protein.  In addition, mass 
spectrometric analysis of p97 shows it to be acetylated on lysine residues within 
the D1 and D2 domains, and mutational analysis has demonstrated a role for 
modification of these residues in influencing ATP binding affinity as well as 
catalysis(Mori-Konya, Kato et al. 2009), which ultimately controls the mechanical 
‘ratcheting’ function of p97. 
   In this chapter, I describe a role for the p97 AAA-ATPase in nuclear 
trafficking of the EGF receptor using coprecipitation and knockdown assays. 
 
RESULTS 
 
P97 Associates with EGF Receptor in an EGF-Dependent Manner 
 
  In order to determine whether p97 may play a role in the Sec61-
dependent EGF receptor nuclear localization, a coprecipitation assay was 
performed which included time points consistent with maximal ligand-dependent 
Sec61-EGF receptor association as previously reported by Liao and Carpenter 
(Liao and Carpenter 2007).  The top panel of Figure 2 shows that 3 hours post-
ligand addition, endogenous p97 maximally associates with endogenous EGF 
receptor in MDA-MB-468 cells.  This finding is consistent with the time course 
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reported for maximal Sec61-EGFR association (Liao and Carpenter 2007).  
Additionally, p97 is shown to be minimally tyrosine phosphorylated at 3 hours 
post-ligand addition (Figure 2, bottom panel), suggesting it may be localized to 
the cytosolic compartment of the cell, based on studies in the yeast homologue 
Cdc48 (Madeo, Schlauer et al. 1998).   
 
Knockdown of p97 Results in Decreased Ligand-Dependent EGF 
Receptor Nuclear Localization 
 
If p97 is required to dislocate the EGF receptor from the translocon, the 
outcome of which is nuclear trafficking, then transient knockdown of p97 should 
result in reduction of ligand-induced nuclear EGF receptor.  Three shRNA clones 
were tested independently for knockdown of endogenous p97 in HEK293 cells 
(Figure 3A).  The non-silencing control shRNA (demonstrated to have no effect 
on gene silencing) and clone 111071 showed no significant reduction in p97 
protein levels, however, the expression of clone 224206 resulted in a significant 
reduction of p97 protein levels.  Specificity of the p97 knockdown is 
demonstrated by the maintenance of tubulin levels as shown in Figure 3A.  In 
Figure 3B, the nuclear fraction prepared from cells expressing both EGF receptor 
and the p97 shRNA clone 224206 shows a substantial reduction in the amount of 
ligand-dependent EGF receptor compared to the nuclear fraction of cells 
expressing EGF receptor only.    Additionally, no substantial change in EGF 
receptor levels is observed in non-nuclear fractions prepared from cells  
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Figure 2.  p97 Associates with EGF Receptor.           
MDA-MB-468 cells were serum-starved and treated 
with EGF for the indicated times.  Cell lysates were 
immunoprecipitated with anti-p97.  Immunoprecipitates 
and lysates were subjected to SDS-PAGE and 
membranes were western blotted with anti-EGFR, 
anti-pY, or anti-p97.  P97 maximally associates with 
EGF receptor and is minimally tyrosine 
phosphorylated at 3 hours post-EGF. 
Red Brewer et al.  Unpublished data (2009) 
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A 
 
B 
 
Figure 3.   p97 Knockdown Reduces Ligand-Dependent Nuclear 
EGF Receptor.    A)  HEK293 cells were transiently transfected with 
the p97 shRNA construct clones indicated and cultured for 72 hours.  
Cells were lysed and lysates subjected to SDS-PAGE.   Membranes 
were western blotted with anti-p97 and anti-tubulin.  B)  HEK293 cells 
ectopically expressing  flag-EGFR with or without a p97shRNA 
construct as indicated were cultured for 60 hours and serum-starved for 
12 hours.  Cells were then treated or not with EGF for 3.5 hours.  Cells 
were fractioned into nuclear and non-nuclear lysates.  Lysates were 
subjected to SDS-PAGE.   Membranes were western blotted with anti-
EGFR, anti-p97, anti-HDAC1 (as a nuclear marker),  and anti-Mkp1 (as 
a cytosolic marker).  Knockdown of p97 results in a significant decrease 
in ligand-dependent nuclear EGF receptor. 
 
 
Red Brewer et al.  Unpublished data (2009) 
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transiently expressing EGF receptor compared to fractions prepared from cells 
transiently expressing EGF receptor and p97 shRNA.  This result indicates that 
p97 is required for ligand-dependent nuclear trafficking of EGF receptor.   
 
p97 Preferentially Associates with a Constitutively Active                                   
EGF Receptor JM Mutant 
 
Given the results in Figure1, that show that EGF receptor association with 
p97 is a ligand-dependent process, I asked whether the tyrosine kinase activity of 
the receptor is required for association with p97.  Cells expressing either wild-
type receptor, the constitutively active mutants V665M or L834R, or the kinase-
dead mutant K721R, were tested for the capacity to associate with p97 at the 
previously determined time point of maximal association, i.e. 3 hours following 
the addition of EGF.  Figure 4 shows that not only does the constitutively active 
V665M mutant receptor associate with p97 more than wild-type receptor, but that 
this increased association remains a ligand-dependent process.  Surprisingly, the 
constitutively active mutant receptor L834R does not associate with p97 in the 
absence or presence of ligand at the given time point.  These results suggest 
that ligand-dependent trafficking of the receptor is required and that p97 may 
possibly recognize specific receptor sequences or conformations.   
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Figure 4.  Ligand-dependent EGFR:p97 Association is 
Augmented by Expression of the Constitutively Active 
EGFR JM Mutant V665M.  HEK293 cells ectopically 
expressing the indicated full-length EGFR receptor cDNA 
constructs were serum-starved and either treated with EGF 
for 3.5 hours or not.  Lysates were immunoprecipitated with 
anti-p97.  Immunoprecipitates and lysates were subjected to 
SDS-PAGE and membranes were western blotted with anti-
EGFR or anti-p97.  EGFR-V665M expressing 293 cells 
exhibit more ligand-dependent p97 association than 
compared to WT. 
 
 
 
 
  
 
 
 
 
 
 
 
  
Red Brewer et al.  Unpublished data (2009) 
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The EGF Receptor Mutant V665M Exhibits Increased Nuclear Localization 
Compared to Wild-Type Receptor 
 
Due to the increased association of p97 with the EGF receptor mutant 
V665M compared to wild-type receptor (Figure 4), as well as the requirement of 
p97 for trafficking of the receptor to the nucleus (Figure 3), I hypothesized that 
this mutant receptor is likely trafficked to the nucleus more efficiently than wild-
type receptor.  Indeed, as shown in Figure 5, western blotting of the nuclear 
fractions of cells expressing either wild-type or the V665M mutant demonstrates 
a significant increase in the levels of mutant EGF receptor in the nuclear fraction 
compared to wild-type.   
 
DISCUSSION 
 
 The nuclear localization of several transmembrane protein ICD fragments, 
such as amyloid precursor protein, Notch, and ErbB-4, have been shown to be 
ligand-dependent processes that result in transcriptional effects in cells and 
mouse models.  The existence of cleavage fragments and the identification of 
proteases required for their formation has resulted in a description of the 
phenomenon known as regulated intramembrane proteolysis (RIP), and has 
served as the prototypical mechanism required for nuclear localization of 
membrane protein fragments.     
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Figure 5.   Ligand-dependent Nuclear Localization of EGFR-
V665M is Greater than WT Receptor.  HEK293 cells ectopically 
expressing either full-length EGF receptor (WT) or the activating JM 
mutant V665M were serum-starved and treated or not with EGF for 
3.5 hours.  Cells were fractioned into nuclear and non-nuclear lysates.  
Lysates were subjected to SDS-PAGE and western blotted with anti-
EGFR, HDAC2 (as a nuclear marker),  or MKP1 (as a cytosolic 
marker).  More full-length EGF receptor containing the V665M 
mutation is shown to localize to the nucleus compared to WT. 
Red Brewer et al.  Unpublished data (2009) 
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 In contrast to RIP, it has been shown more recently that intact EGF 
receptor is localized to the nucleus (Lin, Makino et al. 2001; Liao and Carpenter 
2007).  The presence of intact EGF receptor in the nucleus is coincident with 
upregulation of genes whose protein products can mediate proliferative effects.  
The mechanism for localization of such a large, transmembrane protein to the 
nucleus has led to the discovery of a novel means of receptor trafficking.  The 
Sec61-dependent trafficking of the EGF receptor provides a process in which the 
protein may be liberated from its lipid bilayer environment(Liao and Carpenter 
2007).  Two proteins, heat shock protein 70 and importin-beta, are reported to be 
required for trafficking of the intact receptor to the nuclear compartment(Liao and 
Carpenter 2007).  Data presented here (Figures 2 and 3) are consistent with the 
requirement of the chaperone p97 in the process of nuclear translocation of EGF 
receptor.   
 Data presented in Figure 4 suggests that active tyrosine kinase domain 
conformations may be required for maximal recognition by p97.  Another 
possibility for the differences seen in V665M versus wild-type receptor 
association with p97 may be linked to differences in receptor ubiquitination.  
Upon activation, it is reported that receptor ubiquitination occurs in a site-specific 
manner via the ubiquitin ligase Cbl (Levkowitz, Waterman et al. 1998).  
Additionally, reports have shown that the activated receptor contains both mono- 
and poly-ubiquitin moieties, and mutation of multiple ubiquitin-conjugation sites 
can result in impaired receptor internalization (Huang, Kirkpatrick et al. 2006).  
Given the propensity of p97, and many of its cofactors, for association with 
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ubiquitinated substrates, it is plausible that subpopulations of tyrosine 
phosphorylated and ubiquitinated receptor may be preferential p97 substrates.  
The addition of multiple post-translational modifications may provide a 
mechanism of tightly regulating the trafficking of a relatively small percentage of 
EGF receptor that is localized to the nucleus.  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In this dissertation, I have shown that a specific portion of the 
juxtamembrane sequence of the EGF receptor is required for its activation, and 
thus functions as an activation domain.  Data presented in Chapter 3 (Figures 2, 
3, and 5) illustrate that exon 18-encoded residues of the JM region constitute a 
JMAD and furthermore, that these residues stabilize an active conformation of 
the receptor (Red Brewer, Choi et al. 2009).  This is the first description of a 
juxtamembrane sequence of any RTK acting in an activating, rather than 
inhibitory, manner (Hubbard 2004).  Additional data support the mechanism by 
which a clinically reported JM region mutation effects activation of the receptor 
leading to a transformed phenotype in cell culture and tumorigenesis in athymic 
nude mice (Chapter 3, Figures 6, 7, and 9).  This is the first mutation, outside of 
the tyrosine kinase domain proper, shown to be activating and oncogenic and 
establishes the biological significance of the JMAD. 
These data provide insight into the allosteric requirements for activation of 
the tyrosine kinase, and thus indicate a potential new target for inhibition of the 
kinase by disruption of JMAD residue contacts in the asymmetric dimer.  Figure 
10 of Chapter 3 illustrates the insensitivity of a clinically reported JM mutation to 
the approved EGF receptor-directed chemotherapeutic ATP-mimetic erlotinib.  
The data imply that small molecule inhibitors directed at sites other than the 
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nucleotide binding pocket of the receptor may be effective inhibitors, and would 
inherently have fewer off-target side effects.    
To extend the research presented in this dissertation, I propose using 
peptide inhibitors of the EGF receptor asymmetric dimer interface that include 
residues of the JMAD.  Proof of concept for this mode of allosteric inhibition is 
supplied by the EGF-responsive protein Mig-6.  Mig-6 is reported to associate 
with ErbB-1 and -2 and result in their inactivation (Hackel, Gishizky et al. 2001; 
Anastasi, Sala et al. 2005; Zhang, Pickin et al. 2007).  Short Mig-6 peptides have 
been shown to associate with and inhibit dimer formation of ErbB-1 by preventing 
allosteric contact of tyrosine kinase domain monomers (Zhang, Pickin et al. 
2007)(Table 1).   
Peptide inhibitors used in such a study would include mimics of the JMAD 
as well as the positive control Mig-6 peptide published by the Kuriyan group 
(Zhang, Pickin et al. 2007)(Table 2).  Presumably, a JMAD peptide would have a 
lower affinity for binding to the kinase than a Mig-6 peptide, since Mig-6 
associates with activated receptors to bring about their inactivation, thus 
competing for binding to the same allosteric interface as the JMAD.  A central 
question is whether or not incorporation of a methionine to fill the aliphatic pocket 
created by the donor monomer side-chains of Q788, Y789 and Q825 would 
result in increased peptide binding affinity and/or kinase inhibition, since 
methionine substitution at Val 665 in the JMAD is proposed to constitutively 
activate the kinase by stabilizing the active dimer (Red Brewer, Choi et al. 2009).  
I predict that a chimeric Mig-6/JMAD peptide with a methionine substitution at the 
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position that fills the aliphatic pocket created by the side-chains of Q788, Y789 
and Q825 will result in a more effective peptide (higher affinity/increased kinase 
inhibition) than the use of JMAD-only or Mig-6-only peptides (Table 2).   As with 
the Mig-6 study by the Kuriyan group (2008), fluorescently labeled peptides could 
be tested for association with purified EGF receptor intracellular domain (ICD) 
protein.  A range of concentrations could be tested for association to the ICD 
protein.  Fluorescence polarization experiments would provide data regarding the 
concentrations of peptide(s) required for maximal association of peptide to ICD, 
bearing in mind that the beginning target range for any small molecule inhibitor is 
the 10uM range.  Additionally, analytical ultracentrifugation experiments could be 
conducted to assess the concentration of peptide required to competitively inhibit 
dimer formation.  Using these two methods, both association and inhibition can 
be tested.   
The successful identification of ErbB inhibitory peptides could be used as 
proof of concept for the development of small molecule inhibitor(s).  Identification 
of an allosteric inhibitor has been shown to be effective towards Bcr-Abl (Adrian, 
Ding et al. 2006).  Production of an ErbB-specific allosteric inhibitor would 
presumably target multiple ICD mutations, such as the NSCLC L834R and the 
gatekeeper T776M by preventing dimerization of kinase domain monomers and 
thus, preventing autophosphorylation.  The gatekeeper mutation T776M has 
been described as insensitive to gefitinib.  In this case, mutation results in 
increased ATP affinity as well as steric hindrance of the ATP analog gefitinib 
(Mulloy, Ferrand et al. 2007; Yun, Boggon et al. 2007).  Even in cases where  
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Adapted from Zhang et al.  Nature 450: 741-745  (2007) 
Table 1.  Reported Mig6 Peptides that Exhibit Either Binding (B) and/or Inhibition 
(I) of EGF Receptor Kinase Activity.  Peptides comprised of Mig6 sequence that 
binds in the allosteric dimer interface (‘segment 1’ in red) as well as with the additional 
sequence were tested for both binding (B) to EGFR kinase and inhibition (I) of kinase 
activity using anisotropy and vesicle-based activity assays.  The entire segment 1 
sequence (in red) is required for binding and inhibition of any of the peptides to the WT 
kinase, while the capacity of the peptides to inhibit the L834R mutant requires both 
segments 1 and 2 (336-412). 
 
Table 2.  Proposed Peptides for Binding and Inhibition of ErbB-1 and-2 Kinases.  
A control Mig6 60 residue peptide will be used as a control, since it has been reported 
to result in maximum binding and inhibition of the ErbB-1 kinase (Zhang, Pickin et al. 
2007).  Additional peptides include the JMAD-only, a JMAD/Mig6 chimera, and a JMAD 
V665M/Mig6 chimera. 
84 
 
there is an observed increase of ATP affinity for the kinase, a drug targeting a 
prerequisite activation step would hypothetically be effective.   
Within this dissertation, I have also shown that p97 associates with EGF 
receptor in an EGF-dependent manner at a time point consistent with the 
maximum association of Sec61 with the receptor, and that knockdown of p97 
leads to a significant reduction in nuclear EGF receptor (Chapter IV, Figures 2 
and 3).  The initial hypothesis that p97 functions in dislocation of the receptor 
from the translocon was not testable by the in vitro retrotranslocation assay using 
crude microsome fractions.  In order to place p97 in the Sec61-dependent 
nuclear EGF receptor pathway described by Liao and Carpenter, different 
experimental techniques may be employed (Liao and Carpenter 2007).  For 
instance, further purification of cellular fractions (beyond that of crude 
microsomes) may be necessary to show biochemical evidence of p97 
involvement in the retrotranslocation process.  Purified ER fractions have been 
used to demonstrate the requirement of a functional Sec61 complex as well as 
Hsp70 in the Sec61-dependent pathway (Liao and Carpenter 2007).   
Chemical inhibition of ERAD has been demonstrated with the use of 
eeyarestatin (Wang, Li et al. 2008), which is reported to associate with p97 and 
inhibit the p97-Ufd1-p47 dislocation of substrates from the ER, resulting in an 
accumulation of substrates, such as Ataxin-3, that are normally trafficked in a 
p97-dependent manner to the proteasome for destruction (Wang, Li et al. 2008).  
Use of this compound may provide data that is consistent with the function of p97 
at the ER. 
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 Another unanswered question is how p97 associates with the EGF 
receptor.  Since p97 is known to associate with substrates though cofactors 
and/or ubiquitination, identification of potential cofactors or modification by 
ubiquitin in the Sec61-dependent nuclear localization process would be 
informative.   Figure 4 of Chapter IV demonstrates that the EGF receptor mutant 
V665M associates with p97 more than wild-type receptor at 3.5 hours post-ligand 
addition.  This mutant provides a tool to test the hypothesis that ubiquitin may 
play a role in mediating p97 association.  I hypothesize that the mutant receptor 
will either show an increase in total ubiquitin, or an increase in a different type of 
ubiquitin linkage(i.e. K48-, K63- linked Ub), compared to wild-type receptor.   
 Mapping of the EGF receptor-p97 interaction site may also delineate a 
mode for increased association and nuclear trafficking of the mutant receptor 
(chapter IV, Figures 4 and 5).  A common feature of three p97 interacting 
proteins, Ataxin-3, slow Wallerian degeneration protein, and Hrd1, is the 
requirement of a short N-terminal polybasic sequence.  Truncation of the N-
terminal portions of these substrate proteins results in loss of p97 association 
(Boeddrich, Gaumer et al. 2006; Wilbrey, Haley et al. 2008).  Certainly, such a 
polybasic sequence exists within the juxtamembrane sequence of the EGF 
receptor and comprises a tripartite NLS(Hsu and Hung 2007).  Examination of a 
potential role of the EGF receptor JM-localized polybasic sequence in ligand-
dependent association with p97 is a plausible experimental direction.  Generation 
of purified p97 protein to test association with transiently expressed EGF 
receptor mutants would likely yield information about the required receptor 
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sequence as well as protein(s) in complex with p97 that may be required for 
association with EGF receptor.  It is also possible that the V665M receptor 
preferentially associates with a p97 cofactor that is responsible for nuclear 
trafficking of substrates.   
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